Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kowa Pharmaceuticals America Inc.

Division of Kowa Co. Ltd.
www.kowapharma.com

Latest From Kowa Pharmaceuticals America Inc.

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical

FDA Migraine Guidance Offers ‘Alternative’ Trial Design With Patient-Focused Endpoint

Sponsor would need “no pain” result at two hours, but could use patient-identified symptom as co-primary endpoint.

BioPharmaceutical Clinical Trials

FDA Migraine Guidance Offers ‘Alternative’ Trial Design With Patient-Focused Endpoint

Sponsor would need ‘no pain’ result at two hours, but could use patient-identified symptom as co-primary endpoint.

BioPharmaceutical United States

Amarin Making The Best Of Vascepa As Battle Continues With FDA

The biotech has been making lemonade of its fight with FDA for expanded use of its fish-oil drug Vascepa by upping its promotion of the current indication, but executives continue to sound pessimistic about winning over the agency.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • ProEthic Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Kowa Co. Ltd.
  • Senior Management
  • Benjamin Stakely, Pres. & CEO
    Joseph Barna, CFO
    Brad Hardy, VP, Sales
    Kenneth Riester, VP, Trade & Bus. Dev.
    Lou Mullikin, Chief Commercial Officer
  • Contact Info
  • Kowa Pharmaceuticals America Inc.
    Phone: (334) 288-1288
    530 Industrial Park Blvd.
    Montgomery, AL 36117
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register